Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT00004924
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with irinotecan works in treating patients with advanced non-small cell lung cancer.

Key Dates

Start date
Mar 31, 1999
Status verified
Aug 2009
Completion
Feb 28, 2006

Study Design

Enrollment
28 participants (actual)
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Yale Comprehensive Cancer CenterNew HavenConnecticut06520-8028-
Northwestern Connecticut Oncology-Hematology Associates - TorringtonTorringtonConnecticut06790-

Find similar trials in New Haven, CT

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Yale Comprehensive Cancer Center· New Haven, CTNorthwestern Connecticut Oncology-Hematology Associates - Torrington· Torrington, CT

Related Studies